DHW-221 是一种口服有效的 PI3K/mTOR 双重抑制剂,对四种 I 类 PI3K 亚型及 mTOR(PI3Kα,IC50 = 0.50 nM;PI3Kβ,IC50 = 1.9 nM;PI3Kγ,IC50 = 1.8 nM;PI3Kδ,IC50 = 0.74 nM;mTOR,IC50 = 3.9 nM)均表现出低纳摩尔级别的效力,其通过阻断 PI3K/Akt/mTOR 通路、经内质网应激和 MAPK 信号传导诱导线粒体凋亡和副凋亡以及引起细胞周期阻滞,进而抑制细胞迁移、侵袭和血管生成,从而发挥抗肿瘤作用,在 A549/Taxol 和 HCC827 小鼠模型中均抑制肿瘤生长,可用于非小细胞肺癌 (NSCLC)、结肠癌和乳腺癌的研究。
产品编号: MS-S77203 CAS No.: 2378831-21-9 分子式: C27H22F2N4O5S 分子量: 552.55
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

DHW-221 是一种口服有效的 PI3K/mTOR 双重抑制剂,对四种 I 类 PI3K 亚型及 mTOR(PI3Kα,IC50 = 0.50 nM;PI3Kβ,IC50 = 1.9 nM;PI3Kγ,IC50 = 1.8 nM;PI3Kδ,IC50 = 0.74 nM;mTOR,IC50 = 3.9 nM)均表现出低纳摩尔级别的效力,其通过阻断 PI3K/Akt/mTOR 通路、经内质网应激和 MAPK 信号传导诱导线粒体凋亡和副凋亡以及引起细胞周期阻滞,进而抑制细胞迁移、侵袭和血管生成,从而发挥抗肿瘤作用,在 A549/Taxol 和 HCC827 小鼠模型中均抑制肿瘤生长,可用于非小细胞肺癌 (NSCLC)、结肠癌和乳腺癌的研究。

生物实验数据

生物活性 DHW-221 is an orally effective dual PI3K/mTOR inhibitor that exhibits low-nanomolar potency against all four class I PI3K isoforms and mTOR (PI3Kα, IC50 = 0.50 nM; PI3Kβ, IC50 = 1.9 nM; PI3Kγ, IC50 = 1.8 nM; PI3Kδ, IC50 = 0.74 nM; mTOR, IC50 = 3.9 nM), and it exerts antitumor effects by blocking the PI3K/Akt/mTOR pathway, inducing mitochondrial apoptosis and paraptosis (via endoplasmic reticulum stress and MAPK signaling), and causing cell cycle arrest, thereby inhibiting cell migration, invasion, and angiogenesis; it inhibits tumor growth in both A549/Taxol and HCC827 mouse models and can be used for research on non-small cell lung cancer (NSCLC), colon cancer, and breast cancer.
IC50 & Target PI3Kα:0.50 nM
体外研究
(In Vitro)

DHW-221 (compound 8i) (72 小时) 对典型人类癌细胞表现出抗增殖活性,IC50 值分别为 0.36 μM (T47D)、0.14 μM (HCT116) 和 0.31 μM (MCF-7)。
DHW-221 (0.3-3 μM) 以剂量依赖性方式降低 HCT116 细胞中的磷酸化 Akt (S473),但对总蛋白 Akt 的表达无显著影响。
DHW-221 (0-5 μM,2 周) 以剂量依赖性方式抑制 HCT116 细胞的增殖。
DHW-221 (0.3-3 μM,0-48 小时) 以剂量依赖性方式抑制 HCT116 细胞迁移和侵袭。
DHW-221 (0.3-3 μM) 以浓度依赖性方式诱导 HCT116 细胞凋亡,并伴有明显的核碎裂和染色质凝聚。
DHW-221 能够与 PI3K 激酶的结合位点结合,与 Val882、Lys833 和 Thr887 位点形成氢键,与 Omipalisib (MS-V40329) 类似,并与多个氨基酸残基形成 Pi-Pi 相互作用。
DHW-221 (72 小时) 在 A549/Taxol (IC50 = 0.5274 μM) 和 A549 细胞 (IC50 = 0.4242 μM) 中表现出显著的浓度和时间依赖性细胞毒性。
DHW-221 (0-2.4 μM,48-72 小时) 对 MDR 癌细胞 (A549 和 A549/Taxol 细胞) 具有显著的抑制活性,与对照组相比,48 小时后两种细胞均出现严重的细胞损伤。
DHW-221 (0.15-2.4 μM,48 小时) 以浓度依赖性方式增加 A549/Taxol 细胞内 Rho-123 的积累,并显著下调 P-gp 的表达,表明其抑制 P-gp 的功能和蛋白表达。
DHW-221 (50 nM,48 小时) 显著增强了 Taxol 的细胞毒作用,其作用类似于 P-gp 抑制剂 Verapamil (MS-A46157),表明其既可作为 P-gp 抑制剂,又可作为 MDR 逆转剂。
DHW-221 (0.15-2.4 μM,12-48 小时) 通过线粒体途径、ER 应激和 MAPK 信号通路引发 A549/Taxol 细胞凋亡和副凋亡。
DHW-221 (0.15-2.4 μM,48 小时) 通过下调细胞周期蛋白 cyclin D1、CDK4 和 CDK6 的表达,并上调 p21 的表达,将 A549/Taxol 和 A549 细胞的细胞周期阻滞于 G0/G1 期。
DHW-221 (0.05-0.15 μM,48 小时) 通过逆转上皮-间质转化 (EMT) 表型变化,抑制 A549/Taxol 细胞的迁移和侵袭能力。
DHW-221 (0.15-2.4 μM,48 小时) 显著阻断 A549 和 A549/Taxol 细胞中的 PI3K/Akt 信号通路,表现为 PI3Kp110α 和磷酸化 Akt(p-Akt) 水平降低。
DHW-221 (25-400 nM,1-3 小时) 通过抑制 PI3K/HIF-1α/VEGF 信号轴来抑制 HUVEC 中的内皮管形成。
DHW-221 (1.56-6.25 µM) 在体外大鼠主动脉环实验中抑制微血管出芽。
DHW-221 (1.25-5 µM) 可抑制鸡胚绒毛尿囊膜中的新血管形成,且不影响胚胎活力。

Cell Proliferation Assay

Cell Line: HCT116 cells
Concentration: 0.3, 1 and 3 μM
Incubation Time: 2 weeks
Result: Inhibited the formation of HCT116 cell clones in a concentration-dependent manner.
Almost completely inhibited the production of cell clones at 3 μM.

Cell Migration Assay

Cell Line: HCT116 cells
Concentration: 0.3, 1 and 3 μM
Incubation Time: 0, 24 and 48 h
Result: Its inhibition ability increased in a concentration-dependent manner.

Cell Invasion Assay

Cell Line: HCT116 cells
Concentration: 0.3, 1 and 3 μM
Incubation Time: 48 h
Result: Significantly inhibited HCT116 cell metastasis and invasiveness in a dose-dependent manner.

Cell Viability Assay

Cell Line: A549 and A549/Taxol cells
Concentration: 0.075, 0.15, 0.3, 0.5, 1.2 and 2.4 μM
Incubation Time: 24, 48 and 72 h
Result: Exhibited significant cytotoxicity in a concentration- and time-dependent manner in A549/Taxol and A549 cells with an resistance index (RI) of 1.2.

Cell Proliferation Assay

Cell Line: A549 and A549/Taxol cells
Concentration: 0.15, 0.60 and 2.40 μM
Incubation Time: 2 weeks
Result: Decreased the colony formation ability of A549/Taxol and A549 cells in a concentration-dependent manner.

Cell Cytotoxicity Assay

Cell Line: A549 and A549/Taxol cells
Concentration: 0.15, 0.60 and 2.40 μM
Incubation Time: 48 h
Result: Increased LDH release rates in A549 and A549/Taxol cells in a concentration-dependent manner.

Western Blot Analysis

Cell Line: A549 and A549/Taxol cells
Concentration: 0.15, 0.60 and 2.40 μM
Incubation Time: 3, 6, 12, 24 and 48 h
Result: Upregulated the expression levels of apoptosis-related proteins (cytochrome C, cleaved caspase 3, and cleaved PARP) in A549/Taxol cells in a concentration-dependent manner.
Downregulated the expression levels of the anti-apoptotic protein, Bcl-2, in A549/Taxol cells in a concentration-dependent manner.
Significantly inhibited the expression of Alix in A549/Taxol cells.
Significantly upregulated the expression levels of ATF4, CHOP (key regulator in ER stress), p-JNK, p-ERK, and p-p38 in A549/Taxol cells.
Decreased the expression levels of cyclin D1, CDK4, and CDK6 and increased p21 levels in A549/Taxol cells in a concentration-dependent manner.
Significantly decreased the expression levels of PI3Kp110a and p-Akt in a concentration-dependent manner, with no obvious change in the total Akt level in both cells.
Blocked the PI3K/Akt signaling pathway in both A549/Taxol and A549 cells.
Significantly downregulated p-FOXO3a (Ser253) expression and upregulated FOXO3a expression, accompanied by an increase in Bim expression in A549/Taxol cells.
Showed no significant changes in FOXO3a and Bim expression levels were observed in A549 cells.
Promoted FOXO3a accumulation in A549/Taxol cells when combined with MG132 (MS-L06849).
Interfered with FOXO3a degradation in a proteasome-independent manner.

Immunofluorescence

Cell Line: A549/Taxol cells
Concentration: 0.15, 0.60 and 2.40 μM
Incubation Time: 24 and 48 h
Result: Increased nuclear FOXO3a protein and decreased cytoplasmic phosphorylated FOXO3a at the Ser253 site.
Reversed the EMT phenotype, evidenced by enhanced fluorescence intensity of the epithelial marker occludin and weakened fluorescence of the mesenchymal marker vimentin.

Apoptosis Analysis

Cell Line: A549 and A549/Taxol cells
Concentration: 0.15, 0.60 and 2.40 μM
Incubation Time: 12 h (for vacuolation), and 48 h (for apoptosis/MMP)
Result: Significantly increased the rates of early and late apoptosis in both A549/Taxol and A549 cells after 48 h.
Its pro-apoptotic ability in A549/Taxol cell was stronger than that of A549 cells at 2.4 μM.
Triggered apoptosis in A549/Taxol and A549 cells in a concentration-dependent manner.
Decreased the intracellular MMP in A549/Taxol cells after 48 h.
Induced the formation of massive vacuoles in A549/Taxol cells at 2.4 μM after 12 h.
Attenuated cytoplasmic vacuolation when combined with Cycloheximide (MS-C76056, 20 μM).

Cell Cycle Analysis

Cell Line: A549/Taxol cells
Concentration: 0.15, 0.60 and 2.40 μM
Incubation Time: 48 h
Result: Significantly reduced the proportion of cells in S phase and increased the proportion of cells in G0/G1 phase.

Cell Migration Assay

Cell Line: A549 and A549/Taxol cells
Concentration: 0.05, 0.10 and 0.15 μM
Incubation Time: 0, 24 and 48 h
Result: Significantly decreased the wound healing rate compared to the control group in both A549 and A549/Taxol cells.

Cell Invasion Assay

Cell Line: A549 and A549/Taxol cells
Concentration: 0.05, 0.10 and 0.15 μM
Incubation Time: 24 h
Result: Significantly reduced the number of cells that migrated and invaded through the chamber in A549/Taxol cells.

Western Blot Analysis

Cell Line: A549/Taxol cells
Concentration: 0.05, 0.10 and 0.15 μM
Incubation Time: 48 h
Result: Increased the expression levels of E-cadherin and occludin but significantly decreased the expression levels of mesenchymal markers, including vimentin and slug.
Decreased the expression of transcription factor snail.
Significantly downregulated the expression levels of MMP2 and MMP9 in A549/Taxol cells.
体内研究
(In Vivo)

DHW-221 (10、20 和 40 mg/kg,灌胃,每日一次,持续 2 周) 通过 FOXO3a 核转位,在 A549/Taxol 荷瘤小鼠模型中抑制肿瘤生长,且未引起体重变化和毒性。
DHW-221 (10、20 和 40 mg/kg,口服,每日一次,共 21 天) 可抑制 HCC827 异种移植小鼠模型中的肿瘤生长。

Animal Model: Male nude mice (4-6 weeks old) intravenously injected with A549/Taxol cells
Dosage: 25 and 50 mg/kg
Administration: i.g., q.d. for 2 weeks
Result: Significantly decreased the number of lung nodules.
Downregulated p-FOXO3a expression and upregulated FOXO3a expression.
Showed no change in Ki67 expression.
Showed no significant differences in the body weight and viscera index compared to the control group.
Caused no behavioral abnormalities or loss of appetite.
Exhibited no evident histological abnormalities in the heart, liver, kidney, or spleen.
Resulted in no abnormal toxicity signs in serum biochemical parameters (CK, ALT, AST, CRE), indicating no cardiac, hepatic, or renal toxicity.
Animal Model: Nude mice bearing HCC827 xenografts (Subcutaneous and orthotopic injection)
Dosage: 10, 20 and 40 mg/kg
Administration: p.o., q.d. for 21 days
Result: Significantly inhibited tumor growth in both subcutaneous and orthotopic models.
Showed no significant effect on body weight.
Exhibited only mild liver toxicity at the high dose (40 mg/kg).

化学信息

分子量 552.55
分子式 C27H22F2N4O5S
CAS No. 2378831-21-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础